IKZF1 and plasma cell myeloma: These three agents are approvedby the U.S. FDA to treat multiple myeloma and del(5q) MDS.64,81−84 Molecular glue compounds CC-122, CC-220 (iberdomide), and CC-99282(Table 3) degrade IKZF1and IKZF3 through binding to CRBN E3 ligase.46 These compounds are currently in Phase I/II clinical trials fortreatment of multiple myeloma, non-Hodgkin’s lymphoma, andsystemic lupus erythematosus.70,85−87 CFT7455 (Table 3)is a next-generation IKZF1 and IKZF3 degrader that binds to CRBN E3ligase.